These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 10469679)
1. What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon((R))): a scientific business. Out HJ; Bennink HJ; de Laat WN Hum Reprod; 1999 Sep; 14(9):2189-90. PubMed ID: 10469679 [No Abstract] [Full Text] [Related]
2. What are the clinical benefits of recombinant gonadotrophins? Is Puregon a 'good' or'super' drug? Meniru GI Hum Reprod; 1999 Jun; 14(6):1409-11. PubMed ID: 10357947 [No Abstract] [Full Text] [Related]
3. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study. Tulppala M; Aho M; Tuuri T; Vilska S; Foudila T; Hakala-Ala-Pietilä T; Moilanen J; Bützow T; Kaukoranta S; Söderström-Anttila V; Siegberg R; Suikkari AM; Hovatta O Hum Reprod; 1999 Nov; 14(11):2709-15. PubMed ID: 10548606 [TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Out HJ; Mannaerts BM; Driessen SG; Bennink HJ Hum Reprod; 1995 Oct; 10(10):2534-40. PubMed ID: 8567765 [TBL] [Abstract][Full Text] [Related]
5. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients. Jansen CA; van Os HC; Out HJ; Coelingh Bennink HJ Hum Reprod; 1998 Nov; 13(11):2995-9. PubMed ID: 9853844 [TBL] [Abstract][Full Text] [Related]
6. Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation. Harlin J; Aanesen A; Csemiczky G; Wramsby H; Fried G Hum Reprod; 2002 Feb; 17(2):304-9. PubMed ID: 11821268 [TBL] [Abstract][Full Text] [Related]
7. The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Devroey P; Tournaye H; Van Steirteghem A; Hendrix P; Out HJ Hum Reprod; 1998 Mar; 13(3):565-6. PubMed ID: 9572411 [No Abstract] [Full Text] [Related]
8. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation. Hoomans EH; Andersen AN; Loft A; Leerentveld RA; van Kamp AA; Zech H Hum Reprod; 1999 Oct; 14(10):2442-7. PubMed ID: 10527965 [TBL] [Abstract][Full Text] [Related]
9. Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon). Buckler HM; Robertson WR; Anderson A; Vickers M; Lambert A Hum Reprod; 1999 Dec; 14(12):2969-73. PubMed ID: 10601080 [TBL] [Abstract][Full Text] [Related]
10. New stimulation regimens with recombinant FSH (Puregon) in in-vitro fertilization. Out HJ Eur J Obstet Gynecol Reprod Biol; 1999 Jul; 85(1):21-2. PubMed ID: 10428317 [No Abstract] [Full Text] [Related]
11. Recombinant follicle-stimulating hormone: new biotechnology for infertility. Prevost RR Pharmacotherapy; 1998; 18(5):1001-10. PubMed ID: 9758311 [TBL] [Abstract][Full Text] [Related]
12. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation]. Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561 [TBL] [Abstract][Full Text] [Related]